Pharvaris (PHVS) 7th Annual Evercore ISI HealthCONx Conference summary

Product development and clinical progress

• Developing deucrictibant, an oral bradykinin B2 receptor antagonist, for both prevention and treatment of HAE.

• Two formulations: extended-release tablet for once-daily prophylaxis and immediate-release capsule for on-demand treatment.

• Phase 3 on-demand program (RAPID-3) initiated in March; phase 3 prophylactic program (CHAPTER-3) to start by year-end.

• CHAPTER-3 will enroll 81 participants globally, including adolescents, with a two-to-one randomization.

• Aiming to beat typical 24-month phase 3 timelines, with more guidance expected after study initiation.

Clinical data and efficacy

• Phase 2 prophylaxis (CHAPTER-1) showed 84.5% monthly attack reduction; open-label extension showed 93% reduction.

• Phase 2 on-demand (RAPID-1) showed 2.4-hour time to attack reduction; open-label data showed 1.1-hour reduction and 85% complete resolution within 24 hours.

• Extended-release formulation supports once-daily dosing, aiming to improve compliance and maintain therapeutic levels.

• Bioequivalence and PK studies for the extended-release formulation are complete and support its use in phase 3 and commercial settings.

• Laryngeal attacks included in open-label and will be part of phase 3; more data expected in 2025.

Market opportunity and commercial plans

• Prophylactic HAE market is growing, driven by demand for oral therapies and guideline recommendations.

• On-demand market may stabilize or grow as oral options lower treatment burden and encourage earlier intervention.

• Deucrictibant positioned to offer efficacy, tolerability, and convenience in both prophylaxis and on-demand settings.

• Pricing strategy will be determined after phase 3 data; no major price degradation anticipated.

• Commercial plans in development, with strong community engagement and experienced leadership.